Results 231 to 240 of about 1,566,936 (371)
What's New? Endocrine drugs repurposed from treatment protocols are the primary medications available for breast cancer (BC) prevention in at‐risk women. Adverse effects, however, significantly minimize uptake and prevention impact. Here, the authors investigated licochalcone A (LicA), a non‐endocrine anti‐inflammatory agent with reported hematologic ...
Atieh Hajirahimkhan +14 more
wiley +1 more source
Differences in immunoglobulin utilization when treating patients with primary immune disease in the United States. [PDF]
Farzad R, Ong MS, Farmer JR, Rider NL.
europepmc +1 more source
Assessment of second‐generation MODIS aerosol retrieval (Collection 005) at Kanpur, India
H. Jethva, S. Satheesh, J. Srinivasan
semanticscholar +1 more source
Outcomes and risk factors of hemorrhage in patients with resected brain metastases
What's New? Brain metastases may present with hemorrhage, yet risk factors and clinical outcomes remain unclear. Based on a cohort of 880 patients with resected brain metastases, this study identified tumor volume and primary tumor histology (melanoma and non‐small cell lung cancer) as key predictors of hemorrhage.
Melisa S. Guelen +17 more
wiley +1 more source
Impact of metabolic syndrome and its components on the tumor aggressiveness of renal cell carcinoma. [PDF]
Dogan AE +4 more
europepmc +1 more source
Pubertal timing and incident uterine cancer in the Sister Study cohort
What's New? Younger age at menarche is an established risk factor for uterine cancer. Age at onset of breast development (thelarche), the earliest marker of pubertal estrogen exposure unopposed by progesterone, may also be relevant to uterine cancer risk, but this association has not been explored. Using data from the US prospective Sister Study cohort,
Ariayana N. Harrell +4 more
wiley +1 more source
Compact bacterial recombination complexes drive efficient kilobase-scale knock-in in mammalian cells. [PDF]
Luo Y +12 more
europepmc +1 more source
HIF2A as a prognostic and clinical therapeutic target in ovarian clear cell carcinoma
What's New? Ovarian clear cell carcinoma is highly associated with hypoxia. Hypoxia‐inducible factor 2A (HIF2A) is a key regulator of hypoxic responses, but its role in ovarian clear cell carcinoma remains unclear. This study demonstrated the unfavorable prognostic significance of HIF2A expression in ovarian clear cell carcinoma.
Mengxin Jiang +15 more
wiley +1 more source

